Go Pro
→ Using the IRA/401k unlock guide (From Goldco Direct, LLC) (Ad)tc pixel Free NRSNW Stock Alerts

NeuroSense Therapeutics (NRSNW) Competitors

$0.06 +0.01 (+27.85%)
As of 02:51 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

NRSNW vs. ALVOW, APLMW, ARAV, BIAFW, and BIVIW

Should you buy NeuroSense Therapeutics stock or one of its competitors? NeuroSense Therapeutics's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), bioAffinity Technologies (BIAFW), and BioVie (BIVIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does NeuroSense Therapeutics compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and NeuroSense Therapeutics (NASDAQ:NRSNW) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$491.95MN/AN/AN/AN/A
NeuroSense TherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
AlvotechN/A N/A N/A
NeuroSense Therapeutics N/A N/A N/A

In the previous week, Alvotech had 1 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 1 mentions for Alvotech and 0 mentions for NeuroSense Therapeutics. Alvotech's average media sentiment score of 1.40 beat NeuroSense Therapeutics' score of 0.93 indicating that Alvotech is being referred to more favorably in the media.

Company Overall Sentiment
Alvotech Positive
NeuroSense Therapeutics Positive

Summary

Alvotech beats NeuroSense Therapeutics on 3 of the 3 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Apollomics?

Apollomics (NASDAQ:APLMW) and NeuroSense Therapeutics (NASDAQ:NRSNW) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50MN/AN/AN/AN/A
NeuroSense TherapeuticsN/AN/AN/AN/AN/A

In the previous week, Apollomics' average media sentiment score of 1.87 beat NeuroSense Therapeutics' score of 0.93 indicating that Apollomics is being referred to more favorably in the media.

Company Overall Sentiment
Apollomics Very Positive
NeuroSense Therapeutics Positive

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
NeuroSense Therapeutics N/A N/A N/A

Summary

Apollomics beats NeuroSense Therapeutics on 2 of the 2 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Aravive?

NeuroSense Therapeutics (NASDAQ:NRSNW) and Aravive (NASDAQ:ARAV) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeuroSense TherapeuticsN/AN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

In the previous week, NeuroSense Therapeutics' average media sentiment score of 0.93 beat Aravive's score of 0.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
NeuroSense Therapeutics Positive
Aravive Neutral

Company Net Margins Return on Equity Return on Assets
NeuroSense TherapeuticsN/A N/A N/A
Aravive N/A N/A N/A

Summary

Aravive beats NeuroSense Therapeutics on 2 of the 3 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAFW) and NeuroSense Therapeutics (NASDAQ:NRSNW) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bioAffinity Technologies$5.85MN/AN/AN/AN/A
NeuroSense TherapeuticsN/AN/AN/AN/AN/A

In the previous week, bioAffinity Technologies had 2 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 2 mentions for bioAffinity Technologies and 0 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 0.93 beat bioAffinity Technologies' score of -0.14 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
bioAffinity Technologies Neutral
NeuroSense Therapeutics Positive

Company Net Margins Return on Equity Return on Assets
bioAffinity TechnologiesN/A N/A N/A
NeuroSense Therapeutics N/A N/A N/A

Summary

bioAffinity Technologies beats NeuroSense Therapeutics on 2 of the 3 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to BioVie?

BioVie (NASDAQ:BIVIW) and NeuroSense Therapeutics (NASDAQ:NRSNW) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

In the previous week, BioVie had 1 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 1 mentions for BioVie and 0 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 0.93 beat BioVie's score of 0.29 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
BioVie Neutral
NeuroSense Therapeutics Positive

Company Net Margins Return on Equity Return on Assets
BioVieN/A N/A N/A
NeuroSense Therapeutics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioVieN/AN/AN/AN/AN/A
NeuroSense TherapeuticsN/AN/AN/AN/AN/A

Summary

BioVie and NeuroSense Therapeutics tied by winning 1 of the 2 factors compared between the two stocks.

Get NeuroSense Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NRSNW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRSNW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NRSNW vs. The Competition

Export
MetricNeuroSense TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$4.00B$7.21B$12.70B
Dividend YieldN/A3.61%2.54%11.69%
P/E RatioN/A12.27273.1925.00
Price / SalesN/A1,293.07601.6377.76
Price / CashN/A106.6377.2052.85
Price / BookN/A16.1612.796.08
Net IncomeN/A-$22.72M$3.47B$348.75M
7 Day PerformanceN/A-1.49%-0.32%-1.72%
1 Month PerformanceN/A12.33%7.86%3.51%
1 Year PerformanceN/A52.94%24.53%14.72%

NeuroSense Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NRSNW
NeuroSense Therapeutics
N/A$0.06
+27.9%		N/A-87.8%$0.00N/AN/A10
ALVOW
Alvotech
N/A$0.38
-5.0%		N/AN/A$0.00$491.95MN/A4
APLMW
Apollomics
N/A$0.01
-0.7%		N/A+76.9%$0.00$8.50MN/A59
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
BIAFW
bioAffinity Technologies
N/A$0.11
+42.5%		N/AN/A$0.00$5.85MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NRSNW) was last updated on 9/2/2026 by MarketBeat.com Staff.
From Our Partners
Three companies about to leapfrog Nvidia [And transform the entire industry]
In 1984, a 10000 dollar stake in Apple could have grown to 25 million dollars for early investors who simply g...
Eagle Publishing | Sponsoredtc pixel
Why the Treasury still prices gold at 42 dollars an ounce
The U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...
Golden Portfolio | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Elon just created his own power grid — here’s what’s next
Elon Musk built the largest private power network in American industry history in just 122 days, using a techn...
Banyan Hill Publishing | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
These 3 Stocks Could Soar as Sam Altman Announces New Venture After OpenAI
Elon Musk calls it the most disruptive force in history. Sam Altman is reportedly preparing a new venture afte...
Stansberry Research | Sponsoredtc pixel
Buy this stock tomorrow morning
A new strategy called Sell This, Buy That aims to help investors rotate out of overpriced AI stocks before a p...
Chaikin Analytics | Sponsoredtc pixel
The dollar reset no one told you about
Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...
Porter & Company | Sponsoredtc pixel